Page 13 - Codexis Inc News Today

Synthetic biology —  redesigning the genetic material of organisms —  offers a lot of potential with processes like protein engineering and genetic...

/PRNewswire/ -- The "Specialty Enzymes Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type (Proteases,...

Codexis (NASDAQ:CDXS – Get Rating) and Verde Clean Fuels (NASDAQ:VGAS – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends. Analyst Recommendations This is a breakdown of recent ratings […]

REDWOOD CITY, Calif., June 09, 2023 -- Codexis, Inc. , a leading enzyme engineering company, today announced the approval of equity grants to four new employees as approved by the Compensation... | June 9, 2023

Rare orphan indication Givosiran - rare orphan indication Lumasiran - rare orphan indication ... | June 7, 2023

Global Nucleic Acid Therapeutics CDMO Market to Reach $14.19 Billion by 2033 – BIS Research Market Intelligence Report

Global Nucleic Acid Therapeutics CDMO Market to Reach $14.19 Billion by 2033 – BIS Research Market Intelligence Report

Opaleye Management Inc. lowered its position in Codexis, Inc. (NASDAQ:CDXS – Get Rating) by 17.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 957,500 shares of the biotechnology company’s stock after selling 197,500 shares during the quarter. Codexis makes up […]

StockNews.com upgraded shares of Codexis (NASDAQ:CDXS – Get Rating) from a sell rating to a hold rating in a research note issued to investors on Tuesday. Other equities research analysts also recently issued research reports about the company. HC Wainwright downgraded Codexis from a buy rating to a neutral rating in a report on Tuesday, […]

The rapidly increasing prevalence of chronic diseases around the world is likely to fuel the demand for novel medications and better treatment options, propelling the worldwide market forward. Because of the increased desire for novel treatment options, there has been an increase in the use of drug intermediates as...